ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
New Insights Into Novel Mechanisms Of Action Of Genmab's HuMax-EGFr
Genmab A/S
(CSE: GEN) announced today new insights into the novel mechanisms of action
of its antibody HuMax-EGFr(TM) (zalutumumab). By using Protein
Tomography(TM), a relatively new technology which uses an electron
microscope to view the three dimensional structure of proteins on the
surface of cells, HuMax-EGFr was shown to lock the EGF receptor in an
inactive conformation which prevents receptor activation and the binding of
growth factors. Furthermore, HuMax- EGFr was shown to inhibit EGF receptor
signaling by preventing receptor dimerization, the pairing of two receptor
molecules which starts the signaling cascade. All of these mechanisms have
the potential to interfere with cancer cell growth.
"Coupled with previous findings that HuMax-EGFr is able to induce
potent ADCC and block growth factor binding to EGF receptors, these studies
have given us greater insight into the novel way HuMax-EGFr works," said
Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab.
These data will be presented by Genmab and Sidec Technologies AB, at
the 3rd Novel Solution Seminar for Drug Creation and Development in Tokyo,
Japan on March 12 and in Osaka, Japan on March 14, 2007.
About Genmab A/S
Genmab A/S is a biotechnology company that creates and develops human
antibodies for the treatment of life-threatening and debilitating diseases.
Genmab has numerous products in development to treat cancer, infectious
disease, rheumatoid arthritis and other inflammatory conditions, and
intends to continue assembling a broad portfolio of new therapeutic
products. At present, Genmab has multiple partnerships to gain access to
disease targets and develop novel human antibodies including agreements
with Roche and Amgen. A broad alliance provides Genmab with access to
Medarex, Inc.'s array of proprietary technologies, including the UltiMAb(R)
platform for the rapid creation and development of human antibodies to
virtually any disease target. In addition, Genmab has developed
UniBody(TM), a new proprietary technology that creates a stable, smaller
antibody format. Genmab has operations in Europe and the US. For more
information about Genmab, visit http://www.genmab.com.
This press release contains forward looking statements. The words
"believe", "expect", "anticipate", "intend" and "plan" and similar
expressions identify forward looking statements. Actual results or
performance may differ materially from any future results or performance
expressed or implied by such statements. The important factors that could
cause our actual results or performance to differ materially include, among
others, risks associated with product discovery and development,
uncertainties related to the outcome and conduct of clinical trials
including unforeseen safety issues, uncertainties related to product
manufacturing, the lack of market acceptance of our products, our inability
to manage growth, the competitive environment in relation to our business
area and markets, our inability to attract and retain suitably qualified
personnel, the unenforceability or lack of protection of our patents and
proprietary rights, our relationships with affiliated entities, changes and
developments in technology which may render our products obsolete, and
other factors. Genmab is not under an obligation to up-date statements
regarding the future following the publication of this release; nor to
confirm such statements in relation to actual results, unless this is
required by law.
Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax-
EGFr(TM); HuMax-Inflam(TM); HuMax-CD20(TM); HuMax-TAC(TM); HuMax-HepC(TM),
HuMax-CD38(TM); HuMax-ZP3(TM); and UniBody(TM) are all trademarks of Genmab
A/S.
UltiMAb(R) is a trademark of Medarex, Inc.
Genmab
http://www.genmab.com
Noile descoperiri în roman mecanisme de acþiune al Genmab lui HuMax-RFCE - New Insights Into Novel Mechanisms Of Action Of Genmab's HuMax-EGFr - articole medicale engleza - startsanatate